Feel free to use our complete database with charts, tables and examples.
|Initial U.S. Approval: 2015
Mechanism of Action: The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors.
|INDICATIONS AND USAGE:
REXULTI is indicated for:
• Adjunctive treatment of major depressive disorder (MDD).
• Treatment of schizophrenia
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.